[The distributions of serum HBsAg level in chronic hepatitis B patients based on the China Registry of Hepatitis B (CR-HepB)]

Zhonghua Gan Zang Bing Za Zhi. 2024 Dec 27:32:1-7. doi: 10.3760/cma.j.cn501113-20240723-00337. Online ahead of print.
[Article in Chinese]

Abstract

Objective: To determine the distributions of serum HBsAg level in treatment-naive or treatment-experienced chronic hepatitis B (CHB) patients. Methods: Based on the China Registry of Hepatitis B (CR-HepB), a nationwide hospital-based electronic platform, treatment-naive or treatment-experienced CHB patients who receive nucleos(t)ide analog (NA) therapy were enrolled in our study. We collected patients' clinical characteristics, including demographic, virological and biochemical data. The distributions of HBsAg levels in those two groups were summarized with counts and percentages. Continuous variables were expressed as median (interquartile range, IQR) or mean±SD. Results: A total of 13 505 treatment-naive CHB patients and 6 309 patients with previous NAs therapy were enrolled in the final analysis. The proportion of patients in those two groups with serum HBsAg<100 IU/ml, <500 IU/ml, <1 500 IU/ml or HBsAg level not lower than 1 500 IU/ml, 3 000 IU/ml or 8 000 IU/ml were 10.51% vs. 12.88%, 28.47% vs. 29.84%, 46.85% vs. 52.07%, 53.15% vs. 47.93%, 38.17% vs. 31.77%, 15.62% vs. 10.39%, respectively. HBsAg levels tended to decrease gradually with the duration of antiviral therapy: the percentage of patients with HBsAg levels below 100 IU/ml increased from 12.73% at less than 3 years of treatment to 26.92% at≥10 years of treatment, whereas the percentage of patients with HBsAg levels of 3 000 IU/ml or 8 000 IU/ml and above decreased from 34.66% to 23.08% and from 12.19% to 5.77%, respectively. Conclusions: Our investigation manifested the distribution of the serum HBsAg in treatment-naive CHB patients and patients who received previous NAs treatment. As the duration of antiviral therapy is prolonged, the HBsAg level tends to decrease gradually.

目的: 探索国内初治和经治慢性乙型肝炎(CHB)患者HBsAg水平分布特征。 方法: 数据来源于中国消除乙肝临床研究(CR-HepB)平台,纳入核苷(酸)类似物(NAs)初治和经治CHB患者,收集相关临床资料。分析两类人群的乙型肝炎表面抗原(HBsAg)分布情况,以及不同年龄、不同抗病毒治疗时间的HBsAg水平分布情况。 结果: 共纳入分析13 505例初治患者,6 390例经治患者。HBsAg<100、<500、<1 500 IU/ml的初治患者比例为10.51%、28.47%、46.85%,对应经治患者比例为12.88%、9.84%、52.07%。HBsAg水平≥1 500、≥3 000、≥8 000 IU/ml的初治患者比例为53.15%、38.17%、15.62%,对应经治患者比例为47.93%、31.77%、10.39%。HBsAg水平随抗病毒治疗时间增加,呈现出逐渐降低的趋势。HBsAg<100 IU/ml的经治患者占比从治疗时长不足3年时的12.73%升高至治疗时长≥10年时的26.92%,而HBsAg水平≥3 000 IU/ml或≥8 000 IU/ml患者的比例分别从34.66%降低至23.08%、从12.19%降低5.77%。HBsAg<100、<500及<1 500 IU/ml的患者比例随年龄增加而增加,而HBsAg≥1 500、≥3 000及≥8 000 IU/ml患者的分布占比则依次降低。 结论: 我国NAs初治和经治CHB患者血清HBsAg水平分布情况,且随抗病毒治疗时间延长,HBsAg水平具有逐渐降低的趋势。.

Publication types

  • English Abstract